Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 83.68

+0.1%

Nov 28 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1727)	12/11/2007 12:36:32 PM
From: Jibacoa	Read Replies (2) of 3722

MEDX Is down 20% after it & BMY reported yesterday data from the 3 registrational trials (008, 022, 007) that constitute the monotherapy program for ipilimumab in patients with metastatic melanoma. bigcharts.marketwatch.com The results from study 008, conducted under Special Protocol Assessment (SPA), did not meet the primary endpoint, which was to rule out a best objective response rate of less than 10 percent. However, the totality of data from the registrational program included a clear dose response effect observed in study 022 and best objective response rates across the 3 studies ranging from mid-single digits to mid-teens as determined by independent radiology review. "Given the importance of these findings and the limited treatment options for this patient population, MEDX and BMY are planning to meet with regulatory agencies in the near future. Pending these discussions, the companies aim to submit a regulatory filing to the FDA in the first half of 2008". A CC was scheduled for 8:00 AM today Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next